1. Home
  2. GHC vs ERAS Comparison

GHC vs ERAS Comparison

Compare GHC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graham Holdings Company

GHC

Graham Holdings Company

HOLD

Current Price

$1,132.96

Market Cap

4.8B

Sector

Real Estate

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$13.90

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHC
ERAS
Founded
1877
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
GHC
ERAS
Price
$1,132.96
$13.90
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$14.25
AVG Volume (30 Days)
12.8K
4.8M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
0.65%
N/A
EPS Growth
N/A
36.23
EPS
66.47
N/A
Revenue
$2,932,099,000.00
N/A
Revenue This Year
$7.73
N/A
Revenue Next Year
$4.37
N/A
P/E Ratio
$16.87
N/A
Revenue Growth
N/A
N/A
52 Week Low
$882.21
$1.24
52 Week High
$1,224.76
$24.28

Technical Indicators

Market Signals
Indicator
GHC
ERAS
Relative Strength Index (RSI) 52.22 55.49
Support Level $1,130.17 $12.36
Resistance Level $1,192.14 $15.58
Average True Range (ATR) 29.02 1.14
MACD 0.73 0.19
Stochastic Oscillator 45.60 66.36

Price Performance

Historical Comparison
GHC
ERAS

About GHC Graham Holdings Company

Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: